As biosimilar competition to Johnson & Johnson’s Stelara continues to chew off sales, the much-anticipated launch of the ...

As artificial intelligence continues to rewrite the rules in countless industries, pharma companies are increasingly getting ...

Monday’s FDA approval makes Filspari the first therapy specifically indicated for FSGS, a condition that represents a $1 ...

The FDA has scolded Pfizer over Facebook ads for the cancer drug Adcetris, accusing the Big Pharma of failing to adequately ...

One year into his tumultuous tenure as the FDA’s commissioner, Marty Makary, M.D., has laid out ambitious internal goals and perhaps a more ambitious legislative wish list in his fiscal year 2027 ...

Despite encountering a legal roadblock last month in his effort to rework the U.S. vaccine infrastructure, HHS secretary ...

Most biopharma brands have more approved content than ever before. Yet HCP and patient engagement haven’t kept pace. | Omnichannel isn’t a content problem. It’s an access problem. See how compliant AI ...

AbbVie is spearheading a new battle in pharma’s long-running fight to reform the federal government’s 340B drug discount ...

Robert F. Kennedy Jr. is starting a podcast. Unveiling the show on social media, the Department of Health and Human Services ...

Novartis is launching a three-front push to close healthcare gaps in heart disease and cancer, expanding initiatives with the ...

Fierce Biotech has released its annual ranking of the top 10 pharma R&D budgets of 2025—offering a clear look at which ...

Forget March going out like a lamb. On the M&A landscape, March went out like a lion.  | In a flurry of activity, biopharma ...